Leukemia

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Novel Therapies Needed to Improve TP53-mutant AML Outcomes

By

Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

By

A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

Life Expectancy of Patients With CML Approaching That of General Population

Life Expectancy of Patients With CML Approaching That of General Population

By

In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

By

A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.

Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant Patients

Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant Patients

By

Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

By

Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.

Rituximab Maintenance Prolongs PFS in Patients With CLL

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

By

Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

By

The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

By

Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

By

Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.

Targeted Therapies Suppress T-cell Response But Superagonist Can Overcome the Suppression

Targeted Therapies Suppress T-cell Response But Superagonist Can Overcome the Suppression

By

Dozens of targeted therapies, which are preferred as treatment over chemotherapy and surgery, suppress the activity of T cells that could help to fight tumors.

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

By

Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

By

With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

By

A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.

Research Results Bring Science One Step Closer to Creating Blood Stem Cells in the Laboratory

Research Results Bring Science One Step Closer to Creating Blood Stem Cells in the Laboratory

By

New research has shed light on how the blood is produced in the body, and this work, done in mice, moves science a step closer to manipulation of blood stem cell creation. This could reduce the need for bone marrow transplants, such as those needed by patients with cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs